Kyverna Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Kyverna Therapeutics, Inc. quarterly Share-based Payment Arrangement, Expense history and growth rate from Q1 2023 to Q3 2024.
  • Kyverna Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $3.41M, a 555% increase year-over-year.
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $3.41M +$2.89M +555% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $1.28M +$838K +188% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $2.28K -$466K -99.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q3 2023 $521K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $446K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $468K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.